Trials / Suspended
SuspendedNCT01021943
Spironolactone and Prevention of Calcineurin Inhibitor Toxicity in Kidney Transplant Recipients
The Role of Spironolactone in Prevention of Calcineurin Inhibitor Toxicity in Kidney Transplant Recipients
- Status
- Suspended
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Instituto Nacional de Cardiologia Ignacio Chavez · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main objective of this study is to assess the effect of spironolactone on interstitial fibrosis in kidney transplant recipients receiving calcineurin inhibitors
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | spironolactone | Half of the subjects will be assigned to receive 25 mg of spironolactone for 6 months |
| DRUG | Placebo | Half of the subjects will be assigned to receive placebo for 6 months |
Timeline
- Start date
- 2009-11-01
- First posted
- 2009-12-01
- Last updated
- 2014-07-24
Locations
1 site across 1 country: Mexico
Source: ClinicalTrials.gov record NCT01021943. Inclusion in this directory is not an endorsement.